Search academic texts

Information × Registration Number 0226U001690, (0123U100471) , R & D reports Title To develop an algorithm for immunological and molecular genetic monitoring of patients with Ph-negative myeloproliferative neoplasms in the induction of remission and in patients with Ph-positive chronic myeloid leukemia, who achieved remission with targeted drugs. popup.stage_title Встановити клінічне значення досліджених показників на основі статистичного аналізу отриманих результатів, розробити алгоритм моніторингу мінімально-залишкової хвороби при різних ХМПН. Head Voroniak Myroslav I., Кандидат біологічних наукMasliak Zvenyslava V., Доктор медичних наук Registration Date 29-01-2026 Organization State institution "Institute of blood pathology and transfusion medicine of Nataional Academy of Medical scinces of Ukraine" popup.description1 To develop a system for monitoring of the course of chronic myeloproliferative neoplasias based on the study of immunological and molecular genetic markers of a tumor process, to establish risk factors for the progression of the disease in patients during discontinuation of drug therapy and the occurrence of complications on the background of the use of targeted and immunomodulatory drugs. popup.description2 Object of the study – 32 patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors and 42 patients with myelofibrosis (MF), including 12 patients who received the targeted therapy agent ruxolitinib. Aim of the study – to develop a system for monitoring disease course and assessing treatment effectiveness in patients with CML and MF based on immunological and molecular genetic tumor markers, to identify risk factors for disease relapse, and to elaborate a follow-up algorithm for patients in remission who continue or discontinue therapy. Methods – general clinical, cytological, molecular genetic, enzyme-linked immunosorbent assay, immunophenotyping by flow cytometry, and statistical data analysis methods. Results. A method for immunophenotypic identification of residual leukemic stem cells (CD34⁺CD38⁻CD26⁺) in patients with deep molecular response was developed and implemented. In 32 CML patients, the presence of leukemic stem cells in peripheral blood was detected, indicating persistence of the leukemic clone even during long-term tyrosine kinase inhibitor therapy. The combination of molecular monitoring using RT-qPCR with immunophenotypic analysis increases the sensitivity of minimal residual disease detection and supports its use when planning treatment discontinuation and during further follow-up. In patients with myelofibrosis, the development of cytopenias, immune disorders, and progression of bone marrow fibrosis associated with immunoregulatory cytokines (VEGF, TNF, IL-6, IL-8, IL-10) was confirmed. In patients treated with ruxolitinib for 6–12 months, clinical response was accompanied by decreased levels of VEGF and IL-6 and increased TNF levels, which may be used for monitoring treatment effectiveness and predicting therapy duration. The results of the research demonstrate scientific novelty and practical significance and may be implemented in clinical practice.A total of 36 scientific publications were published Product Description popup.authors Shurko Nataliia O Danysh Olha Yo. Simonova Mar'iana I. Tomashevska Nataliia Ya. Мельник М.І. Kokoruz Mar'iana V. Khudzii Sofiia S. Thir Hrystyna R Shelep Nataliia V. Boiko Olha I. popup.nrat_date 2026-01-29 Close